Early Edge: Amgen, Potash Corp., Geron Corporation, and Clean Energy Fuels Corp.

The drug company lowered its 2010 revenue forecast, citing weakness in the euro

by Elizabeth Harrow (eharrow@sir-inc.com) 7/30/2010 9:20 AM



Today's column includes the latest quarterly results from Amgen, Inc. (AMGN), a wave of post-earnings price-target adjustments on Potash Corp. of Saskatchewan (POT), a major FDA-related boost for Geron Corporation (GERN), and a negative analyst note for Clean Energy Fuels Corp. (CLNE). Each day, Early Edge focuses on the hot stocks in the news and gives you a unique insight into each stock's sentiment backdrop. Our time-tested contrarian approach centers on options, and gives you the trading tools to approach the day with a much-needed edge over the investing herd.

Amgen, Inc.

Amgen, Inc. (AMGN) unveiled its second-quarter results after Thursday's closing bell, with the drug maker reporting a profit of $1.2 billion, or $1.25 per share, down about 5.3% from the year-ago quarter. Excluding items, earnings arrived at $1.38 per share, exceeding analysts' expectations for a profit of $1.30 per share. Likewise, AMGN's revenue of $3.80 billion surpassed Wall Street's consensus estimate of $3.74 billion.

AMGN price chartLooking ahead, AMGN downwardly revised its revenue forecast for 2010, citing weakness in the euro. The firm previously predicted full-year revenue of $15.1 billion to $15.5 billion, but sales are now expected to arrive "slightly below" the low end of that range. U.S. health care reforms are expected to have an impact of $200 million to $250 million on 2010 revenues.

AMGN has dipped fractionally lower ahead of the bell as traders consider the quarterly report. The equity is currently struggling beneath the weight of double-barreled resistance at its 50-day and 80-day moving averages, which have collaborated to push AMGN lower since late April.

Puts were popular Thursday ahead of AMGN's earnings release, with volume rising to 1.57 times the norm -- but these weren't necessarily bearish bets. The stock's out-of-the-money August 52.50 put saw 4,367 contracts change hands, with 73% crossing at the bid price. Open interest at this strike swelled overnight by 2,117 contracts, suggesting that traders sold to open puts here as a neutral-to-bullish pre-earnings play.

Potash Corp. of Saskatchewan

Potash Corp. of Saskatchewan (POT) has attracted a trio of price-target adjustments this morning, one day after the fertilizer firm hiked its 2010 earnings outlook. UBS raised its price target from $112 to $120 and reiterated its "buy" rating, while Soleil Securities upped its target from $89 to $100. Meanwhile, National Bank took the road less traveled by cutting POT's price target from $127 to $120.

POT settled at $102.80 on Thursday, and Thomson Reuters pegs the equity's average 12-month price target at $118.81. The shares are modestly lower in pre-market trading, backing away from recent resistance at their 50-week moving average.

Long-term bulls set their sights on POT in the wake of Thursday's earnings report, as evidenced by a large increase in open interest at the equity's out-of-the-money January 2011 120-strike call. More than 4,200 contracts traded here yesterday, with 52% trading at the ask price, and open interest jumped overnight by 3,104 contracts.

However, short-term bears were equally emphatic. Overnight, POT's weekly July 30, 2010-expiration 100-strike put added 1,215 contracts to open interest -- and most of the volume at this strike Thursday changed hands at the ask price, implying these soon-to-expire puts were most likely purchased.

Receive FREE access to Schaeffer’s
Sentiment Spring 2009
premier online options magazine!
Featured Companies






Partner Center

tribal fussion